Renal cell oncocytoma tumor evolutions: a case report
This report delineates the clinical progression of a renal oncocytoma in a 38-year-old female, initially asymptomatic, over a three-year follow-up period following her treatment for papillary thyroid cancer. The timeline of this case is as follows: In 2016, the patient was treated with total thyroidectomy and I131 for thyroid cancer. During an annual follow-up, an incidental renal mass was detected via FDG PET/CT, initially characterized as a benign, non-FDG-avid renal oncocytoma. Over two years, this lesion demonstrated a remarkable increase in FDG uptake and a slight growth in size, coupled with new I131 uptake in subseq...
Source: Frontiers in Oncology - March 1, 2024 Category: Cancer & Oncology Source Type: research

Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
(Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 1, 2024 Category: Cancer & Oncology Source Type: research

Nanoparticles transfected with plasmid-encoded lncRNA-OIP5-AS1 inhibit renal ischemia-reperfusion injury in mice via the miR-410-3p/Nrf2 axis
This study aimed to investigate the effects of the plasmid-encoded lncRNA-OIP5-AS1@PDA nanoparticles (POP-NPs) on renal ischemia/reperfusion (RI/R) injury and explore the underlying mechanisms. RI/R or OGD/R models were established in mice and HK-2 cells, respectively. In vivo, vector or POP-NPs were administered (10 nmol, IV) 48 h after RI/R treatment. In the RI/R mouse model, the OIP5-AS1 and Nrf2/HO-1 expressions were down-regulated, while miR-410-3p expression was upregulated. POP-NPs treatment effectively reversed RI/R-induced renal tissue injury, restoring altered levels of blood urea nitrogen, creatinine, malondiald...
Source: Renal Failure - February 29, 2024 Category: Urology & Nephrology Authors: Rongjie Zhang Xin Zhang Xuhui Zhu Tao Li Yansheng Li Peng Zhang Yuanhao Chen Gao Li Xiuwu Han Source Type: research

Impact of Tumor Grade Distribution on Genetic Alterations in Clear Cell Renal Cell Carcinoma and Prostate Cancer
CONCLUSION: Our results suggest the importance of selecting the maximum distribution of higher tumor grade areas to obtain results on the precise gene alterations for genomics-focused treatments.PMID:38423595 | DOI:10.21873/cgp.20441 (Source: Genomics Proteomics ...)
Source: Genomics Proteomics ... - February 29, 2024 Category: Genetics & Stem Cells Authors: Kosuke Mizutani Seiji Sugiyama Koji Kameyama Shingo Kamei Shigeaki Yokoi Akemi Morikawa Makoto Takeuchi Kensaku Seike Toru Yamada Hidetoshi Ehara Seiya Sawada Kouseki Hirade Hirohito Furuta Kengo Matsunaga Tetsuya Yamada Ippei Sakamoto Yasutaka Kato Hiros Source Type: research

Advanced Renal Cell Carcinoma With Inferior Vena Cava Thrombus Treated With a Combination of Preoperative Lenvatinib and Pembrolizumab
CONCLUSION: Treatment with lenvatinib and pembrolizumab combination therapy led to tumor shrinkage and allowed robot-assisted nephrectomy in a patient with advanced RCC with the IVC tumor thrombus extending to the right atrium, corroborating the efficacy of the treatment.PMID:38423655 | DOI:10.21873/anticanres.16927 (Source: Cell Research)
Source: Cell Research - February 29, 2024 Category: Cytology Authors: Chika Nagahisa Kazuhiko Yoshida Hanae Kondo Takayuki Nakayama Shinsuke Mizoguchi Ryo Minoda Hironori Fukuda Yuki Kobari Junpei Iizuka Yoji Nagashima Hideki Ishida Toshio Takagi Source Type: research